Related references
Note: Only part of the references are listed.18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/ NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
Elin Pauwels et al.
JOURNAL OF NUCLEAR MEDICINE (2023)
Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT
Jiale Hou et al.
EJNMMI RESEARCH (2021)
[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
Elin Pauwels et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Automated GMP compliant production of [18F]AlF-NOTA-octreotide
Terence Tshibangu et al.
EJNMMI RADIOPHARMACY AND CHEMISTRY (2020)
Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms
Tingting Long et al.
CLINICAL NUCLEAR MEDICINE (2019)
Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient
Elin Pauwels et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
The Search for an Alternative to [68Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of 18F-labeled Somatostatin Analog Development
Christopher M. Waldmann et al.
THERANOSTICS (2019)
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Neuroendocrine Tumor Therapy: Lu-177-DOTATATE
Erik S. Mittra
AMERICAN JOURNAL OF ROENTGENOLOGY (2018)
Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years
Paul E. Sackstein et al.
SEMINARS IN ONCOLOGY (2018)
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA
Murat Fani Bozkurt et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Physics of pure and non-pure positron emitters for PET: a review and a discussion
Maurizio Conti et al.
EJNMMI PHYSICS (2016)
Exploring the Rising Incidence of Neuroendocrine Tumors: A Population-Based Analysis of Epidemiology, Metastatic Presentation, and Outcomes
Julie Hallet et al.
CANCER (2015)
Clinical applications of Gallium-68
Sangeeta Ray Banerjee et al.
APPLIED RADIATION AND ISOTOPES (2013)
Planning cancer control in Latin America and the Caribbean
Paul E. Goss et al.
LANCET ONCOLOGY (2013)
Optimized labeling of NOTA-conjugated octreotide with F-18
Peter Laverman et al.
TUMOR BIOLOGY (2012)
Targeting Somatostatin Receptors: Preclinical Evaluation of Novel 18F-Fluoroethyltriazole-Tyr3-Octreotate Analogs for PET
Julius Leyton et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
Thorsten D. Poeppel et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Equivalence and Noninferiority Testing in Anesthesiology Research
Edward J. Mascha
ANESTHESIOLOGY (2010)
A Novel Facile Method of Labeling Octreotide with 18F-Fluorine
Peter Laverman et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
Share Paper
